WALTHAM, Mass., Feb. 20, 2018 -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that its fourth quarter and full year 2017 financial results will be released on Tuesday, February 27, 2018 before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments.
Dial-in Number
U.S./Canada Dial-in Number: (877) 412-6083
International Dial-in Number: (702) 495-1202
Conference ID: 5496159
Replay Dial-in Number: (855) 859-2056
Replay International Dial-in Number: (404) 537-3406
Conference ID: 5496159
A telephone replay will be available from approximately 11:00 a.m. ET on February 27, 2018 through midnight on March 5, 2018.
The webcast with slides will be accessible through the Investors section of the company’s website at www.amagpharma.com. A replay of the webcast will be archived on the website for 30 days.
About AMAG
AMAG is a biopharmaceutical company focused on developing and delivering important therapeutics, conducting clinical research in areas of unmet need and creating education and support programs for the patients and families we serve. Our currently marketed products support the health of patients in the areas of maternal and women’s health, anemia management and cancer supportive care. Through CBR®, we also help families to preserve newborn stem cells, which are used today in transplant medicine for certain cancers and blood, immune and metabolic disorders, and have the potential to play a valuable role in the ongoing development of regenerative medicine. For additional company information, please visit www.amagpharma.com.
AMAG Pharmaceuticals® is a registered trademark of AMAG Pharmaceuticals, Inc. CBR® is a registered trademark of Cbr Systems, Inc.
AMAG Pharmaceuticals Contact:
Christi Waarich
Associate Director, Investor Relations
617-498-7638


ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 



